Huiyu Pharmaceutical released its 2026 interim report. The company's total operating revenue was 552 million yuan, net profit attributable to the parent company was 57.6486 million yuan, and net cash inflow from operating activities was 91.5207 million yuan. The company's latest asset-liability ratio was 28.56 percent, up 2.05 percentage points from the previous quarter and up 4.91 percentage points from the same period last year. The latest gross margin was 76.74 percent, down 2.43 percentage points from the previous quarter and down 2.66 percentage points from the same period last year. The latest return on equity was 1.55 percent. Diluted earnings per share were 0.09 yuan. The latest total asset turnover was 0.11 times, and the latest inventory turnover was 0.45 times, down 8.71 percent from the same period last year. The company had 16,500 shareholders, and the top ten shareholders held 319 million shares, accounting for 50.95 percent of total share capital.
Sichuan Huiyu Pharmaceutical Co LtdInterim report shows net profit of 57.65M yuan, but margins and turnover declined, mixed signals.
